论文部分内容阅读
应用抗P16抑癌基因产物的单克隆抗体对子宫内膜癌石蜡标本 6 0份进行免疫组化测定 ,同时采用流式细胞术 (FCM)对其DNA含量和SPF进行定量分析 ,并与临床病理资料进行对比。结果表明 :P16蛋白阳性部位主要在子宫内膜癌细胞浆内 ,阳性率为 70 .0 % ,低于正常子宫内膜和非典型增生者 (P <0 .0 5 ) ,其表达程度与子宫内膜癌临床分期、细胞分级、转移和DNA倍体水平等预后因素有关 (P <0 .0 1)。提示 :P16抑癌基因的突变或缺失导致P16蛋白合成障碍 ,引起细胞恶变 ,P16蛋白表达测定及DNA倍体和SPF定量分析有助于患者的预后估计。
Sixty copies of paraffin-embedded specimens of endometrial cancer were detected by immunohistochemistry using anti-P16 tumor suppressor gene monoclonal antibody, and their DNA content and SPF were quantitatively analyzed by flow cytometry (FCM) Data comparison. The results showed that the positive expression of P16 protein was mainly in the cytoplasm of endometrial cancer cells, with a positive rate of 70.0%, which was lower than that of normal endometrium and atypical hyperplasia (P <0.05) Endometrial cancer clinical stage, cell grade, metastasis and DNA ploidy and other prognostic factors (P <0. Tip: Mutations or deletions of P16 suppressor gene lead to P16 protein synthesis obstacles, causing cell malignant, P16 protein expression and DNA ploidy and SPF quantitative analysis contribute to the prognosis of patients.